Biodexa Pharmaceuticals Plc (BDRX) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

Biodexa Pharmaceuticals Plc (BDRX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $544,662, listed on NASDAQ, employing roughly 11 people, carrying a beta of 1.19 to the broader market. Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Led by Stephen Anthony Stamp, public since 2015-12-07.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for BDRX as of 2026-09-22; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →